Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : JAG201
Therapeutic Area : Neurology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Jaguar Gene Therapy to Start Pediatric Trial for ASD and Phelan-McDermid Syndrome
Details : JAG201 is an investigational gene replacement therapy for autism with SHANK3 mutations or deletions, administered via a one-time unilateral ICV injection, targeting the entire brain and spinal cord.
Product Name : JAG201
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
September 07, 2024
Lead Product(s) : JAG201
Therapeutic Area : Neurology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : JAG201
Therapeutic Area : Neurology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Jaguar Gene Therapy Clears IND for JAG201 in Autism Spectrum Disorder
Details : JAG201 is in preclinical studies for SHANK3-mutated autism and Phelan-McDermid syndrome, delivering SHANK3 via AAV9 vector.
Product Name : JAG201
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
January 31, 2024
Lead Product(s) : JAG201
Therapeutic Area : Neurology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : JAG101
Therapeutic Area : Genetic Disease
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Preclinical studies support continued development of JAG101, an investigational gene therapy designed to address the root cause of Type 1 galactosemia and reduce multiple toxic metabolites.
Product Name : JAG101
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
May 16, 2022
Lead Product(s) : JAG101
Therapeutic Area : Genetic Disease
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : JAG101
Therapeutic Area : Genetic Disease
Study Phase : Preclinical
Sponsor : Eli Lilly
Deal Size : $139.0 million
Deal Type : Series B Financing
Details : Jaguar will use Series B funding proceeds to continue to advance its initial pre-clinical pipeline, which utilizes the proven and well-characterized AAV9 vector to target diseases in larger patient populations with significant unmet need.
Product Name : JAG101
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
April 13, 2021
Lead Product(s) : JAG101
Therapeutic Area : Genetic Disease
Highest Development Status : Preclinical
Sponsor : Eli Lilly
Deal Size : $139.0 million
Deal Type : Series B Financing
Lead Product(s) : JAG101
Therapeutic Area : Genetic Disease
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Jaguar Gene Therapy is focused on advancing its initial pre-clinical pipeline of AAV9-based gene therapies which includes JAG101, JAG201, JAG301, AXV101 focusing on key therapeutic areas such as galactosemia, autism spectrum disorder, Type 1 diabetes and...
Product Name : JAG101
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
February 25, 2021
Lead Product(s) : JAG101
Therapeutic Area : Genetic Disease
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable